The ingredients of AN-845 are all generic drugs, therefore it is quite safe. Our first indication focuses on pancreatic cancer so that the development schedule can be shortened according to 505(b)2 and orphan drug regulations. In our plan, the license will be obtained within 3 years. Next, AN-845 will be applied to other cancer indications in the future to expand the scope and value.
